Lifeline Scientific, Inc French national tender win (3128B)

TIDMLSI

RNS Number : 3128B

Lifeline Scientific, Inc

03 March 2014

3 March 2014

Lifeline Scientific, Inc.

("Lifeline" or the "Company")

French national tender win

Lifeline Scientific (AIM: LSI, LSIC), the transplantation technology company, announces that its wholly owned subsidiary, Organ Recovery Systems, has been awarded a major national tender to supply LifePort(R) Kidney Transporters ('LifePort') and related products to 23 renal transplant programmes in France. This is the first national tender award in the EU for the Company.

The competitive tender was organized by UniHA, France's largest Health Cooperative Group, in co-operation with the French national authority for transplantation, L'Agence de la Biomédecine. The tender for the supply of machine preservation products followed the publication of clinical guidelines in France for machine perfusion of all deceased donor expanded criteria ('ECD') kidneys. ECDs are medically viable donors who present with one or more comorbidities such as age, hypertension, or diabetes mellitus.

In France, approximately half of donated kidneys come from ECDs. LifePort machine perfusion of ECD kidneys has been shown to improve patient outcomes, by reducing the risk of delayed graft function ('DGF') and increasing graft survival.(1,2) DGF is known to adversely impact near and long term graft performance and survival rates.

The tender award is for a three year term with a one year renewal option. It calls for Organ Recovery Systems to provide LifePort Kidney Transporters, plus, installation, commissioning and maintenance of machinery, consumables and accessories for perfusion and transport of kidneys.

LifePorts are presently employed by surgeons in over 160 transplant programmes across 27 countries, with over 47,000 clinical procedures to date. France is the largest market in Europe for kidney transplants with 2,687 deceased donor kidney transplant procedures reported in 2012.

David Kravitz, CEO of Lifeline Scientific, commented:

"We are delighted to have won this competitive tender in Europe's largest renal transplant market. We are grateful for the opportunity to provide technology that will help the French transplant surgical community bring life changing benefits to transplant patients."

References:

1. Moers C et al. N Engl J Med 2009; 360(1): 7-19.

2. Moers C et al. N Engl J Med 2012; 366(8): 770-771.

 
 Lifeline Scientific, Inc.                                       www.lifeline-scientific.com 
 David Kravitz, CEO                                                     Tel: +1 847 294 0300 
 Lisa Kieres, CFO                                                       Tel: +1 847 294 0300 
 
 Panmure Gordon (UK) Limited                                        Tel: +44 (0)20 7886 2500 
 Freddy Crossley/Fred Walsh (Corporate 
  Finance) 
 Adam Pollock (Corporate Broking) 
 
 Walbrook                                Tel: +44 (0)20 7933 8780 or lifeline@walbrookpr.com 
 Paul McManus                                                       Mob: +44 (0)7980 541 893 
 Mike Wort                                                          Mob: +44 (0)7900 608 002

About Lifeline Scientific Inc.

Lifeline Scientific, Inc. is a Chicago-based global medical technology company with regional offices in Brussels and Sao Paulo. The Company's focus is the development of innovative products that improve transplant outcomes and lower the overall costs of transplantation. Its lead product is the market-leading and clinically validated LifePort Kidney Transporter. Devices for preservation of the liver, pancreas, heart and lung are in late stage pre-clinical development. For more information please visit www.lifeline-scientific.com

About LifePort Kidney Transporter

Created with the challenges of organ recovery and transport in mind, LifePort Kidney Transporter is a proprietary medical device designed to provide improved kidney preservation, evaluation and transport prior to transplantation. Today, it is widely recognised as the world's leading machine preservation device for kidneys. Employed by surgeons in over 160 leading transplant programmes in 27 countries worldwide, LifePorts have successfully preserved over 47,000 kidneys indicated for clinical transplant. For more information please visit www.organ-recovery.com

Lifeline Scientific, Inc. Shares

As a US Company listed on the London Stock Exchange's AIM exchange, Lifeline Scientific, Inc. (AIM: LSI, LSIC) trades under two lines of stock. While affiliates of the Company are required to hold restricted (RegS) shares, all others may hold restricted or unrestricted shares. Unrestricted shares may be electronically traded through the CREST system. Both lines of stock have identical rights, preferences and privileges. Non-affiliates may transfer restricted shares to the unrestricted line after purchase through the Company's registrar. Total shares outstanding for the Company at this time are 19,446,959.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCLLLLBZXFXBBK

Lifeline Sci. S (LSE:LSI)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024